A detailed history of Wynn Capital, LLC transactions in Biogen Inc. stock. As of the latest transaction made, Wynn Capital, LLC holds 1,576 shares of BIIB stock, worth $274,854. This represents 0.2% of its overall portfolio holdings.

Number of Shares
1,576
Previous 1,576 -0.0%
Holding current value
$274,854
Previous $365 Million 16.38%
% of portfolio
0.2%
Previous 0.27%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 18, 2024

SELL
$190.52 - $236.72 $2,857 - $3,550
-15 Reduced 0.94%
1,576 $365 Million
Q1 2024

Apr 10, 2024

SELL
$212.02 - $267.71 $35,407 - $44,707
-167 Reduced 9.5%
1,591 $343 Million
Q4 2023

Feb 01, 2024

BUY
$222.59 - $267.94 $391,313 - $471,038
1,758 New
1,758 $455 Million

Others Institutions Holding BIIB

About BIOGEN INC.


  • Ticker BIIB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 144,000,992
  • Market Cap $25.1B
  • Description
  • Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...
More about BIIB
Track This Portfolio

Track Wynn Capital, LLC Portfolio

Follow Wynn Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wynn Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Wynn Capital, LLC with notifications on news.